Stock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut

Stock Track05-05

GeneDx Holdings Corp. (WGS) stock plummeted 46.19% in Tuesday's pre-market session, following a sharp post-market decline the previous day. The severe sell-off was triggered by the company's disappointing first-quarter 2026 financial results and a substantial reduction in its full-year revenue outlook.

The rare disease genomics firm reported Q1 revenue of $102.3 million, which represented a 17% year-over-year increase but fell significantly short of analyst consensus estimates of approximately $112-113 million. Furthermore, GeneDx posted an adjusted loss per share of $0.28, badly missing the expected loss of $0.01, and reported a GAAP net loss of $63.3 million for the quarter.

Investor sentiment was heavily impacted by management's decision to drastically lower its full-year 2026 revenue guidance. The company now expects revenue in the range of $475 million to $490 million, a sharp reduction from the previous outlook of $540 million to $555 million. In response to the disappointing results and revised forecast, several analysts cut their price targets on the stock, including Guggenheim, Jefferies, Canaccord Genuity, BTIG, Wells Fargo, and Craig-Hallum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109042860?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109042860","market":"nz","top_or_hot":-1,"title":"Stock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut","media":"Stock Track","content":"<p>GeneDx Holdings Corp. (WGS) stock plummeted 46.19% in Tuesday's pre-market session, following a sharp post-market decline the previous day. The severe sell-off was triggered by the company's disappointing first-quarter 2026 financial results and a substantial reduction in its full-year revenue outlook.</p><p>The rare disease genomics firm reported Q1 revenue of $102.3 million, which represented a 17% year-over-year increase but fell significantly short of analyst consensus estimates of approximately $112-113 million. Furthermore, GeneDx posted an adjusted loss per share of $0.28, badly missing the expected loss of $0.01, and reported a GAAP net loss of $63.3 million for the quarter.</p><p>Investor sentiment was heavily impacted by management's decision to drastically lower its full-year 2026 revenue guidance. The company now expects revenue in the range of $475 million to $490 million, a sharp reduction from the previous outlook of $540 million to $555 million. In response to the disappointing results and revised forecast, several analysts cut their price targets on the stock, including Guggenheim, Jefferies, Canaccord Genuity, BTIG, Wells Fargo, and Craig-Hallum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-05 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GeneDx Holdings Corp. (WGS) stock plummeted 46.19% in Tuesday's pre-market session, following a sharp post-market decline the previous day. The severe sell-off was triggered by the company's disappointing first-quarter 2026 financial results and a substantial reduction in its full-year revenue outlook.</p><p>The rare disease genomics firm reported Q1 revenue of $102.3 million, which represented a 17% year-over-year increase but fell significantly short of analyst consensus estimates of approximately $112-113 million. Furthermore, GeneDx posted an adjusted loss per share of $0.28, badly missing the expected loss of $0.01, and reported a GAAP net loss of $63.3 million for the quarter.</p><p>Investor sentiment was heavily impacted by management's decision to drastically lower its full-year 2026 revenue guidance. The company now expects revenue in the range of $475 million to $490 million, a sharp reduction from the previous outlook of $540 million to $555 million. In response to the disappointing results and revised forecast, several analysts cut their price targets on the stock, including Guggenheim, Jefferies, Canaccord Genuity, BTIG, Wells Fargo, and Craig-Hallum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"","article_id":"1109042860","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109042860","pubTimestamp":1777989301,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GeneDx Holdings Corp. (WGS) stock plummeted 46.19% in Tuesday's pre-market session, following a sharp post-market decline the previous day. The severe sell-off was triggered by the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"个股追踪|GeneDx Holdings盘前暴跌46.19%因Q1营收未达预期且大幅下调全年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1},"content_text":"GeneDx Holdings Corp. (WGS) stock plummeted 46.19% in Tuesday's pre-market session, following a sharp post-market decline the previous day. The severe sell-off was triggered by the company's disappointing first-quarter 2026 financial results and a substantial reduction in its full-year revenue outlook.The rare disease genomics firm reported Q1 revenue of $102.3 million, which represented a 17% year-over-year increase but fell significantly short of analyst consensus estimates of approximately $112-113 million. Furthermore, GeneDx posted an adjusted loss per share of $0.28, badly missing the expected loss of $0.01, and reported a GAAP net loss of $63.3 million for the quarter.Investor sentiment was heavily impacted by management's decision to drastically lower its full-year 2026 revenue guidance. The company now expects revenue in the range of $475 million to $490 million, a sharp reduction from the previous outlook of $540 million to $555 million. In response to the disappointing results and revised forecast, several analysts cut their price targets on the stock, including Guggenheim, Jefferies, Canaccord Genuity, BTIG, Wells Fargo, and Craig-Hallum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109042860","isCrawlerRequest":true}